The compound you've described, **[5-[4-[(5-methyl-2-furanyl)methylamino]-6-quinazolinyl]-2-furanyl]methanol**, is a complex organic molecule with a rather unwieldy name.
Unfortunately, without more context or information about the research being conducted, it's impossible to definitively state why this specific compound is important.
**However, we can speculate based on its structural features:**
* **Quinazoline core:** Quinazolines are a common structural motif in pharmaceuticals, often associated with biological activities like anti-cancer, anti-inflammatory, and anti-bacterial properties.
* **Furan rings:** Furan rings, especially substituted ones like in this compound, can contribute to the molecule's interaction with biological targets.
* **Amino group:** The amino group in this molecule suggests potential for hydrogen bonding interactions, crucial for binding to receptors or enzymes.
* **Methanol group:** The methanol group could affect the compound's solubility or metabolic fate within a biological system.
**To understand the specific importance of this compound, we need more information, such as:**
* **What research area is it being used in?** (e.g., drug development, material science, organic chemistry, etc.)
* **What are the specific biological activities being investigated?** (e.g., enzyme inhibition, receptor binding, antimicrobial effects, etc.)
* **What is the compound's mechanism of action?** How does it interact with the target?
**Possible research areas where this compound might be relevant:**
* **Drug development:** As a potential lead compound for new pharmaceuticals with therapeutic potential.
* **Organic chemistry:** As a starting material for synthesizing other complex molecules or exploring novel chemical reactions.
* **Materials science:** As a component of functional materials with unique properties.
**Overall, [5-[4-[(5-methyl-2-furanyl)methylamino]-6-quinazolinyl]-2-furanyl]methanol is a complex organic compound with potential for diverse applications, but its specific importance depends on the context of the research it is involved in.**
| ID Source | ID |
|---|---|
| PubMed CID | 44968231 |
| CHEMBL ID | 1604618 |
| CHEBI ID | 93138 |
| SCHEMBL ID | 1675234 |
| Synonym |
|---|
| ml167 |
| NCGC00188654-01 |
| NCGC00188654-02 |
| CHEMBL1604618 , |
| bdbm50342913 |
| (5-(4-((5-methylfuran-2-yl)methylamino)quinazolin-6-yl)furan-2-yl)methanol |
| BRD-K64835161-001-01-0 |
| S7509 , |
| cid 44968231 |
| 1285702-20-6 |
| SCHEMBL1675234 |
| (5-(4-(((5-methylfuran-2-yl)methyl)amino)quinazolin-6-yl)furan-2-yl)methanol |
| ml-167 |
| CS-7710 |
| ncgc00188654 |
| cid44968231 |
| AKOS027422750 |
| CHEBI:93138 |
| HMS3653F11 |
| NCGC00188654-04 |
| SW220083-1 |
| HY-15951 |
| [5-[4-[(5-methyl-2-furanyl)methylamino]-6-quinazolinyl]-2-furanyl]methanol |
| Q27164857 |
| E73462 |
| FT-0731734 |
| EX-A2103 |
| AS-16662 |
| BCP08599 |
| HMS3744K03 |
| CCG-267859 |
| [5-[4-[(5-methylfuran-2-yl)methylamino]quinazolin-6-yl]furan-2-yl]methanol |
| SB60879 |
| EN300-6479790 |
| [5-(4-{[(5-methylfuran-2-yl)methyl]amino}quinazolin-6-yl)furan-2-yl]methanol |
| AC-35934 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| quinazolines | Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| dual specificity tyrosine-phosphorylation-regulated kinase 1A isoform 1 | Homo sapiens (human) | Potency | 12.8102 | 0.0130 | 7.4878 | 29.1922 | AID2705; AID493206; AID504424 |
| dual specificity protein kinase CLK2 isoform 2 | Homo sapiens (human) | Potency | 1.6480 | 0.1730 | 0.7983 | 1.6480 | AID504427 |
| dual specificity tyrosine-phosphorylation-regulated kinase 1B isoform p69 | Homo sapiens (human) | Potency | 4.4200 | 0.0730 | 1.6480 | 4.4200 | AID504429 |
| dual specificity protein kinase CLK4 | Homo sapiens (human) | Potency | 0.1863 | 0.0116 | 3.7867 | 31.6228 | AID1970; AID493204; AID504421 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Dual specificity protein kinase CLK1 | Homo sapiens (human) | IC50 (µMol) | 1.5220 | 0.0074 | 0.4344 | 2.1000 | AID594076 |
| Dual specificity protein kinase CLK2 | Homo sapiens (human) | IC50 (µMol) | 1.6480 | 0.0005 | 0.7554 | 8.0380 | AID594077 |
| Dual specificity protein kinase CLK3 | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0410 | 2.0143 | 8.7440 | AID594078 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0031 | 0.7140 | 9.0120 | AID594049 |
| Dual specificity protein kinase CLK4 | Homo sapiens (human) | IC50 (µMol) | 0.1360 | 0.0110 | 1.0694 | 7.9430 | AID1851272; AID594050 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1B | Homo sapiens (human) | IC50 (µMol) | 4.4200 | 0.0010 | 0.5851 | 4.4200 | AID594079 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID594050 | Inhibition of Clk4 kinase using ATP as substrate by 33P radiolabeled kinase assay | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10 | Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk). |
| AID594076 | Inhibition of Clk1 kinase using ATP as substrate by 33P radiolabeled kinase assay | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10 | Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk). |
| AID594079 | Inhibition of Dyrk1B kinase using ATP as substrate by 33P radiolabeled kinase assay | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10 | Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk). |
| AID1851272 | Inhibition of CLK4 (unknown origin) | 2022 | Bioorganic & medicinal chemistry, 09-15, Volume: 70 | Exploring the roles of the Cdc2-like kinases in cancers. |
| AID594049 | Inhibition of Dyrk1A kinase using ATP as substrate by 33P radiolabeled kinase assay | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10 | Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk). |
| AID594078 | Inhibition of Clk3 kinase using ATP as substrate by 33P radiolabeled kinase assay | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10 | Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk). |
| AID594077 | Inhibition of Clk2 kinase using ATP as substrate by 33P radiolabeled kinase assay | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10 | Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.80) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||